Alba EspargarÃ³

List of Publications by Year
in descending order

51 papers	1,630 citations	236925 25 h-index	302126 39 g-index
51 all docs	51 docs citations	51 times ranked	2359 citing authors

#	Article	IF	Citations
1	Inclusion bodies: Specificity in their aggregation process and amyloid-like structure. Biochimica Et Biophysica Acta - Molecular Cell Research, 2008, 1783, 1815-1825.	4.1	131
2	Bacterial Inclusion Bodies of Alzheimer's Disease Î²â€Amyloid Peptides Can Be Employed To Study Nativeâ€Like Aggregation Intermediate States. ChemBioChem, 2011, 12, 407-423.	2.6	90
3	Detection of transient proteinâ€“protein interactions by bimolecular fluorescence complementation: The Abl-SH3 case. Proteomics, 2007, 7, 1023-1036.	2.2	85
4	Combined in Vitro Cell-Based/in Silico Screening of Naturally Occurring Flavonoids and Phenolic Compounds as Potential Anti-Alzheimer Drugs. Journal of Natural Products, 2017, 80, 278-289.	3.0	68
5	Magnetic Nanoparticles Cross the Blood-Brain Barrier: When Physics Rises to a Challenge. Nanomaterials, 2015, 5, 2231-2248.	4.1	67
6	Natural Xanthones from Garcinia mangostana with Multifunctional Activities for the Therapy of Alzheimerâ€™s Disease. Neurochemical Research, 2016, 41, 1806-1817.	3.3	59
7	Novel Levetiracetam Derivatives That Are Effective against the Alzheimer-like Phenotype in Mice: Synthesis, in Vitro, ex Vivo, and in Vivo Efficacy Studies. Journal of Medicinal Chemistry, 2015, 58, 6018-6032.	6.4	58
8	Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting Î²-amyloid, tau, and cholinesterase pathologies. European Journal of Medicinal Chemistry, 2014, 84, 107-117.	5.5	57
9	The in Vivo and in Vitro Aggregation Properties of Globular Proteins Correlate With Their Conformational Stability: The SH3 Case. Journal of Molecular Biology, 2008, 378, 1116-1131.	4.2	56
10	Study and selection of in vivo protein interactions by coupling bimolecular fluorescence complementation and flow cytometry. Nature Protocols, 2008, 3, 22-33.	12.0	51
11	Thioflavin-S staining coupled to flow cytometry. A screening tool to detect in vivo protein aggregation. Molecular BioSystems, 2012, 8, 2839.	2.9	47
12	Thioflavin-S Staining of Bacterial Inclusion Bodies for the Fast, Simple, and Inexpensive Screening of Amyloid Aggregation Inhibitors. Current Medicinal Chemistry, 2014, 21, 1152-1159.	2.4	44
13	Effect of the surface charge of artificial model membranes on the aggregation of amyloid Î²-peptide. Biochimie, 2012, 94, 1730-1738.	2.6	40
14	Design, synthesis and multitarget biological profiling of second-generation anti-Alzheimer rheinâ€“huprine hybrids. Future Medicinal Chemistry, 2017, 9, 965-981.	2.3	40
15	Discovery of Novel Inhibitors of Amyloid Î²-Peptide 1â€“42 Aggregation. Journal of Medicinal Chemistry, 2012, 55, 9521-9530.	6.4	39
16	The Role of Protein Sequence and Amino Acid Composition in Amyloid Formation: Scrambling and Backward Reading of IAPP Amyloid Fibrils. Journal of Molecular Biology, 2010, 404, 337-352.	4.2	38
17	Characterization of the amyloid bacterial inclusion bodies of the HET-s fungal prion. Microbial Cell Factories, 2009, 8, 56.	4.0	37
18	Shogaolâ€“huprine hybrids: Dual antioxidant and anticholinesterase agents with Î²-amyloid and tau anti-aggregating properties. Bioorganic and Medicinal Chemistry, 2014, 22, 5298-5307.	3.0	37

#	Article	IF	Citations
19	Ultra rapid in vivo screening for anti-Alzheimer anti-amyloid drugs. Scientific Reports, 2016, 6, 23349.	3.3	37
20	On the Binding of Congo Red to Amyloid Fibrils. Angewandte Chemie - International Edition, 2020, 59, 8104-8107.	13.8	36
21	Dual Inhibitors of Amyloid-Î² and Tau Aggregation with Amyloid-Î² Disaggregating Properties: Extended <i>In Cellulo</i>, <i>In Silico</i>, and Kinetic Studies of Multifunctional Anti-Alzheimerâ€™s Agents. ACS Chemical Neuroscience, 2021, 12, 2057-2068.	3.5	36
22	Studies on bacterial inclusion bodies. Future Microbiology, 2008, 3, 423-435.	2.0	34
23	Using bacterial inclusion bodies to screen for amyloid aggregation inhibitors. Microbial Cell Factories, 2012, 11, 55.	4.0	33
24	Native Structure Protects SUMO Proteins from Aggregation into Amyloid Fibrils. Biomacromolecules, 2012, 13, 1916-1926.	5.4	28
25	Yeast prions form infectious amyloid inclusion bodies in bacteria. Microbial Cell Factories, 2012, 11, 89.	4.0	26
26	A novel class of multitarget anti-Alzheimer benzohomoadamantaneâ€'chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors. European Journal of Medicinal Chemistry, 2019, 180, 613-626.	5.5	26
27	Histidineâ€Rich Oligopeptides To Lessen Copperâ€Mediated Amyloidâ€Î² Toxicity. Chemistry - A European Journal, 2016, 22, 7268-7280.	3.3	25
28	Centrally Active Multitarget Anti-Alzheimer Agents Derived from the Antioxidant Lead CR-6. Journal of Medicinal Chemistry, 2020, 63, 9360-9390.	6.4	25
29	Kinetic and thermodynamic stability of bacterial intracellular aggregates. FEBS Letters, 2008, 582, 3669-3673.	2.8	24
30	Energy barriers for HETâ€s prion forming domain amyloid formation. FEBS Journal, 2009, 276, 5053-5064.	4.7	23
31	Deciphering the role of the thermodynamic and kinetic stabilities of SH3 domains on their aggregation inside bacteria. Proteomics, 2010, 10, 4172-4185.	2.2	23
32	Thiosemicarbazone Derivatives as Inhibitors of Amyloid-Î² Aggregation: Effect of Metal Coordination. Inorganic Chemistry, 2020, 59, 6978-6987.	4.0	20
33	Key Points Concerning Amyloid Infectivity and Prion-Like Neuronal Invasion. Frontiers in Molecular Neuroscience, 2016, 9, 29.	2.9	19
34	Evidence of Protein Adsorption in Pegylated Liposomes: Influence of Liposomal Decoration. Nanomaterials, 2017, 7, 37.	4.1	19
35	Temperature Dependence of the Aggregation Kinetics of Sup35 and Ure2p Yeast Prions. Biomacromolecules, 2012, 13, 474-483.	5.4	18
36	New Pyrimidine and Pyridine Derivatives as Multitarget Cholinesterase Inhibitors: Design, Synthesis, and <i>In Vitro</i> and <i>In Cellulo</i> Evaluation. ACS Chemical Neuroscience, 2021, 12, 4090-4112.	3.5	16

#	ARTICLE	IF	CITATIONS
37	In vivo amyloid aggregation kinetics tracked by timeâ€lapse confocal microscopy in realâ€time. Biotechnology Journal, 2016, 11, 172-177.	3.5	14
38	Amyloid Pan-inhibitors: One Family of Compounds To Cope with All Conformational Diseases. ACS Chemical Neuroscience, 2019, 10, 1311-1317.	3.5	14
39	Dual Effect of Prussian Blue Nanoparticles on AÎ²40 Aggregation: Î²-Sheet Fibril Reduction and Copper Dyshomeostasis Regulation. Biomacromolecules, 2021, 22, 430-440.	5.4	11
40	On the Binding of Congo Red to Amyloid Fibrils. Angewandte Chemie, 2020, 132, 8181-8184.	2.0	11
41	Could<i>Î±</i>-Synuclein Amyloid-Like Aggregates Trigger a Prionic Neuronal Invasion?. BioMed Research International, 2015, 2015, 1-7.	1.9	10
42	Investigation into the stability and reactivity of the pentacyclic alkaloid dehydroevodiamine and the benz-analog thereof. Tetrahedron, 2016, 72, 2535-2543.	1.9	9
43	Pharmacophore Modeling and 3D-QSAR Study of Indole and Isatin Derivatives as Antiamyloidogenic Agents Targeting Alzheimerâ€™s Disease. Molecules, 2020, 25, 5773.	3.8	9
44	Screening for Amyloid Aggregation: In-Silico, In-Vitro and In-Vivo Detection. Current Protein and Peptide Science, 2014, 15, 477-489.	1.4	9
45	Predicting the aggregation propensity of prion sequences. Virus Research, 2015, 207, 127-135.	2.2	7
46	Bacterial Inclusion Bodies for Anti-Amyloid Drug Discovery: Current and Future Screening Methods. Current Protein and Peptide Science, 2019, 20, 563-576.	1.4	7
47	Aggregation of the neuroblastoma-associated mutant (S120G) of the human nucleoside diphosphate kinase-A/NM23-H1 into amyloid fibrils. Naunyn-Schmiedeberg's Archives of Pharmacology, 2011, 384, 373-381.	3.0	5
48	Amyloids in solid-state nuclear magnetic resonance: potential causes of the usually low resolution. International Journal of Nanomedicine, 2015, 10, 6975.	6.7	5
49	Azobioisosteres of Curcumin with Pronounced Activity against Amyloid Aggregation, Intracellular Oxidative Stress, and Neuroinflammation. Chemistry - A European Journal, 2021, 27, 6015-6027.	3.3	4
50	Design, Synthesis, and In Vitro, In Silico and In Cellulo Evaluation of New Pyrimidine and Pyridine Amide and Carbamate Derivatives as Multi-Functional Cholinesterase Inhibitors. Pharmaceuticals, 2022, 15, 673.	3.8	3
51	Synthesis, In Vitro Profiling, and In Vivo Efficacy Studies of a New Family of Multitarget Anti-Alzheimer Compounds. Proceedings (mdpi), 2019, 22, .	0.2	0